Skip
HTB

HIV treatment bulletin

RSS 2 RSS Atom Atom • ISSN 1472-4683 • SubscribeAbout

Conference reports

Superinfection identified in 2 out of 8 patients with unexpected viral load increases

Simon Collins, HIV i-Base

The rate and risk of reinfection with a second strain of HIV after primary infection are unclear with most instances reported as case studies. While reinfection clearly occurs, with viral load of the transmitting partner likely to be a significant risk factor, the clinical importance of a second infection, based on current limited data, appears largely related to acquisition of a resistant strain and its impact on reducing treatment options.

A pilot
study by Doyle and colleagues at UCL looked for treatment-naive patients who were at risk of reinfection from sexual exposure, who experienced a significant viral load increase (>0.5 log) during routine viral load clinic monitoring. Eight patients were indentified (all sub-type B) and phylogenetic analyses were performed on the stored and most recent samples.
In two patients, early sequences formed separate clusters to late sequences, with no evidence of viral recombination, indicating a second infection.

One patient was reinfected 5 months after his initial diagnosis during acute infection, and experienced similar seroconversion symptoms at the time of viral load increase. He also acquired syphilis and herpes in the subsequent 6 months.

A second patient had been diagnosed HIV-positive 3 years earlier and experienced no symptoms and no other STIs at the time of superinfection. He controlled both the fifirst infection and the superinfection without HAART, with a set-point viral load of 3.5 log10 copies/mL and a stable CD4 count >1000 cells/mm3.

These two cases indicate that reinfection is unlikely to be a rare event and can occur both in the early and established disease, even in the presence of effective immune responses.

COMMENT

While the study conclusion is that targeted screening based upon sexual history and viral load can achieve a high detection rate and is important in the context of transmitted resistance, it is not appropriate to conclude that early HAART should be used as a public health measure between consenting HIV-positive adults who choose to use neither condoms nor treatment.

Ref: Doyle T et al. High-risk sexual behaviour and HIV-1 superinfection: an indication for early initiation of antiretroviral therapy? Poster abstract P150.

Links to external websites are current at time of posting but not maintained.

HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info